Abstract:In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure–activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01137.Listing the metabolic stability of the preferred compounds (Table S1); listing binding affinities of 48 with 110 protein kinases (Table S2); listing the disease activity index (DAI) scoring system (Table S3); listing the IL-6, TNF-α, and IL-10 concentrations in Serum of UC Mice (Table S4); listing the primer sequence (Table S5); listing the docking results of compounds 48, 8, and 11 (Figure S1); listing the inhibition patterns of compound 48 and different drugs on different phosphorylated STATs (Figure S2); listing the relative gray quantitative analysis of p-STATs after treatment of 48 (Figure S3); listing the inhibitory effect of compound 48 on the p-STAT3 after cytokine stimulation (Figure S4); listing the in vivo assays of tissue distribution mice (Figure S5); listing the HE staining of heart, liver, spleen, lungs, and kidneys (Figure S6); listing the detection of levels of proteins in the colon tissue of UC mice by western blot (Figure S7); listing the effect of 48 on the expression of Th1, Th2, and Th17 cells (Figure S8); listing the HPLC of compounds 8, 33, 41, 48, and 49, respectively (Figures S9–S13); listing F-NMR spectra of compound 48 (Figure S14) (PDF)jmcmar_mfs (CSV)Compound 48-JAK1-6DBN (PDB)Compound 48-TYK2-6DBK (PDB)Compound 8-JAK1-6DBN (PDB)Compound 8-TYK2-6DBK (PDB)Compound 11-JAK1-6DBN (PDB)Compound 11-TYK2-6DBK (PDB)This article has not yet been cited by other publications.

Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives As Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis.

Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis Treatment.

The discovery of a novel pyrrolo[2,3- b ]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis

Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.

Structure-based optimization of indoline-containing compounds as second generation inhibitors of NF-κB-inducing kinase (NIK)

Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model

Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)

Small-molecule inhibitors of protein kinase C, the Janus kinases (JAK) pathway and phosphodiesterases in the treatment of psoriasis

Design and Synthesis of Novel Aminoindazole-pyrrolo[2,3- b]pyridine Inhibitors of IKKα That Selectively Perturb Cellular Non-Canonical NF-κB Signalling

Development of selective heterocyclic PDE4 inhibitors for treatment of psoriasis

The discovery of quinoline derivatives, as NF-κB inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Structure‐guided design of potent JAK1‐selective inhibitors based on 4‐amino‐7H‐pyrrolo[2,3‐d]pyrimidine with anti‐inflammatory efficacy

Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines As Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.

Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment

Identification and study of new NF‐κB‐inducing kinase ligands derived from the imidazolone scaffold

Novel RNA polymerase I inhibitor CX-5461 suppresses imiquimod-induced experimental psoriasis

Design, Synthesis, and Biological Activity of Novel Quinone Derivatives as Potent STAT3 Inhibitors for Psoriasis Treatment

Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation